Please login to the form below

Not currently logged in
Email:
Password:

ALK-Abello and WAO establish allergy research award

ALK-Abello, in collaboration with the World Allergy Organisation (WAO), has established a new global allergy research award

Danish allergy immunotherapy company, ALK-Abello, in collaboration with the World Allergy Organisation (WAO), has established a new global allergy research award. "The WAO Henning Leowenstein Research Award" will be presented biennially to a research scientist who has shown excellence in the field of allergy in terms of contributing research results of potential significance for the future understanding and treatment of allergy.

Dr Michael A Kaliner, President of the WAO said: "Our mission is to be a global resource and advocate in the field of allergy, advancing excellence in clinical care, education, research and training. By presenting an important scientific award in collaboration with ALK-Abello, we hope to encourage more scientists to focus on this important scientific area."

The WAO Henning Loewenstein Research Award is named after allergy research pioneer Henning Lowenstein, who took decisive part in the ground breaking discovery of new methods for allergen standardisation in the 1970s and was former executive vice-president of research at ALK-Abello.

The WAO Henning Loewenstein Research Award of EUR 20,000 will be presented for the first time at the World Allergy Congress (WAC) in Bangkok, from 2 to 6 December 2007. A travel grant to attend the World Allergy Congress and Awards Dinner will also be offered to the winner. The award builds on the tradition of a former research award that was introduced in 1999 in celebration of Henning Loewenstein's 25th anniversary at ALK-Abello.

Scientists are invited to apply for the award and the applications will be evaluated by an international scientific board. Application guidelines for the 2007 award are available at www.alk-abello.com/award and the deadline is 30 June 2007.

Former winners include:

  • Dr Mark Larche (UK), Imperial College was honoured for his work with the analysis of peptide-based immunotherapy for allergic asthma (2000)
  • Dr Eckard Hamelmann (Germany), Humboldt-University of Berlin, was honoured for his contribution to the use of murine models for the study of allergen-mediated sensitisation, airway inflammation and airway hyper-responsiveness (2001)
  • Dr Miriam Fleur Moffatt (UK), University of Oxford, was honoured for her studies of the genetics of specific allergy focusing on the role of the T-cell receptor genes, the HLA genes and the beta-chain gene of the high affinity receptor for IgE (2002)
  • Dr Erika Ganglberger (Austria), University of Vienna, was honoured for her research activities in the development of a novel treatment for type I allergy based on mimotope technology (2003)
  • Dr Christopher Lynn Kepley (US), Commonwealth University of Virginia, was honoured for his research activities in mechanisms regulating Fc?RI secretion from mast cells and basophils (2004)
  • Dr Omid Akbari (US), Harvard University, was honoured for his research into cellular and molecular mechanisms involved in the regulation of allergic inflammation and representing the immunological basis of allergic asthma (2005)

7th June 2007

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To transform lives through communication that changes behaviour and improves health outcomes....

Latest intelligence

Flu
Influenza – the risk to vulnerable populations
Why we can't get complacent about flu vaccination...
dementia
Alzheimer’s Research UK highlights socio-economic inequalities in dementia risk
The charity aims to improve the number of women participating in dementia research and grow awareness of dementia risk factors...
Data security
Concerns about data security are building a strong case for clinical mobility in EMEA
Electronic medical records have transformed the storage of sensitive information but how can the healthcare sector continue to protect patient and staff data?...